The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics

Blood Cancer Journal

Volumn 3, Issue 5, 2013, Pages

  How, J ^a   Sykes, J ^a   Minden, M D ^a   Gupta, V ^a   Yee, K W L ^a   Schimmer, A D ^a   Schuh, A C ^a   Kamel Reid, S ^a   Brandwein, J M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; Chemotherapy; FLT3 mutation; Leukemia; NPM1 mutation

Indexed keywords

FLT3 LIGAND; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL SURVIVAL; CLINICAL FEATURE; CYTOGENETICS; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RETROSPECTIVE STUDY;

EID: 84878285783     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.14     Document Type: Article

References (20)

1. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074-3080.
2. Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Uhn. Blood 2002; 100: 4372-4380.
3. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli C. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733-3739.
4. Verhaak RGW, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005; 106: 3747-3754.
5. Palmisano M, Grafone T, Ottaviani E, Testoni N, Baccarani M, Martinelli G et al. NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukaemia. Haematologica 2007; 92: 1268-1269.
6. Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini BW et al. Minimal residual disease levels assessed by NPM1 mutaiton-specific RQ-PCR provide important prognostic information in AML. Blood 2009; 114: 2220-2231.
7. Shih L, Huang C, Wu J, Lin TL, Po Dunn P, Wang PN et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002; 100: 2387-2392.
8. Chevallier P, Prebet T, Pigneux A, Hunault M, Delaunay J, Perry F et al. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. Leukemia 2010; 24: 467-469.
9. Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Sakura T, Kanamori H et al. Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. Haematologica 2010; 85: 1857-1864.
10. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075-4083.
11. How J, Sykes J, Gupta V, Yee KWL, Schimmer AD, Schuh AC et al. Influence of FLT3-ITD allele burden and white blood count on outcome in patients with intermediate-risk karyotype acute myeloid leukemia (AML). Cancer 2012; 118: 6110-6117.
12. Brandwein JM, Gupta V, Schuh AC, Schimmer AD, Yee K, Xu W et al. Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy. Am J Hematol 2007; 83: 54-58.
13. Grigg AP, Szer J, Beresford J, Dodds A, Bradstock K, Durrant S et al. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. Br J Haematol 1999; 107: 409-418.
14. Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000; 14: 476-479.
15. Ferrara F, Palmieri S, Mele G. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica 2004; 89: 998-1008.
16. Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O'Brien S, Koller C et al. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res 2010; 34: 752-756.
17. Chevallier P, Labopin M, Turlure P, Prebet T, Pigneux A, Hunault A et al. A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogenous leukaemia patients: a GOELAMS study. Leukemia 2011; 25: 939-944.
18. Schnittger S, Bacher U, Kern W, Alpermann T, Haferlach C, Haferlach T. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia 2011; 25: 1297-1304.
19. Levis M, Ravandi F, Wang ES, Baer MR, Alexander Perl A, Coutre S et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011; 117: 3294-3301.
20. Cortes JE, Perl AE, Smith CC, Kovacsovics T, Dombret H, Dohner H et al. A phase II open-label, AC220 monotherapy efficacy study in patients with refractory/relapsed Flt3-Itd positive acute myeloid leukemia: updated interim results. Blood 2011; 114: 2576a.